Objective: To investigate the correlation between serum 25 hydroxyvitamin D (25 (OH) D) and peripheral neuropathy of type 2 diabetes (Diabetic Peripheral N europathy, DPN) and its predictive value for DPN. Methods: The subjects were divided into deficient group, insufficient group and normal group, and the relationship between 25(OH)D and DPN and the correlation of 25(OH)D and DPN with various indicators were analyzed. Results: Comparing the DPN group with the NDPN group, 25(OH)D3(22.10±0.77ng/ml vs 24.45±0.66ng/ml), 25(OH)D total (23.12±0.74ng/ml vs 25.68±0.67ng/ml), BMI, RHR, TG, FT3, BUN between the two groups (P <0.05), 25(OH)D3,25(OH)D total, FT3, BMI, and RHR are risk factors for DPN. The ROC curve showed that the optimal cutoff for 25(OH)D3 predicting DPN in T2DM was 18.85ng/ml (AUC 0.76,95% CI 0.697-8.823) and the optimal cutoff for 25(OH)D predicting T2DM was 19.94ng/ml (AUC 0.765,95% CI 0.703-0.828).    Conclusion: 25(OH)D can be used as a simple and effective screening method to predict the occurrence of DPN for total 25(OH)D<19.94ng/ml or 25(OH)D3<18.85ng/ml.

The authors have declared no competing interest.

N

Yes

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The studies involving humans were approved by the ethics committee of Zhangzhou Affiliated Hospital of Fujian Medical University.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All relevant data are included in the manuscript and its supporting information files